Definium Therapeutics, Inc. (DFTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Definium Therapeutics, Inc. on September 8, 2026. The report addresses a significant regulatory milestone for the Company's lead drug candidate, DT120 ODT, intended for the treatment of major depressive disorder.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or operational financial data.
Material Changes
On September 8, 2026, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the Company's DT120 ODT program. This designation is intended to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions.
Outlook, Risks, and Management Commentary
Management highlighted the FDA's Breakthrough Therapy Designation as a key validation of the DT120 ODT program. The filing incorporates a press release (Exhibit 99.1) detailing this announcement. No specific financial guidance, risk factors, or contingencies were disclosed within the text of this specific 8-K filing.
Investor Verification Checklist
- Verify the specific criteria met by DT120 ODT to receive Breakthrough Therapy Designation.
- Review the attached Press Release (Exhibit 99.1) for details on the next steps in the clinical development timeline.
- Confirm the current cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor for any subsequent filings regarding the impact of this designation on the Company's partnership or licensing opportunities.